

Elisabet Svenungsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8806705/publications.pdf>

Version: 2024-02-01

188
papers

9,191
citations

61857

43
h-index

45213

90
g-index

190
all docs

190
docs citations

190
times ranked

8846
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.5	1,265
2	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1296-1304.	0.5	664
3	EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 476-485.	0.5	590
4	Anticardiolipin Antibodies Predict Early Recurrence of Thromboembolism and Death Among Patients with Venous Thromboembolism Following Anticoagulant Therapy. <i>American Journal of Medicine</i> , 1998, 104, 332-338.	0.6	481
5	Risk Factors for Cardiovascular Disease in Systemic Lupus Erythematosus. <i>Circulation</i> , 2001, 104, 1887-1893.	1.6	450
6	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	5.8	314
7	Global epidemiology of systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2021, 17, 515-532.	3.5	229
8	Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. <i>Arthritis and Rheumatism</i> , 2005, 52, 192-200.	6.7	211
9	Periodontitis Increases the Risk of a First Myocardial Infarction. <i>Circulation</i> , 2016, 133, 576-583.	1.6	200
10	A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. <i>Human Molecular Genetics</i> , 2008, 17, 2868-2876.	1.4	183
11	Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor I α /tumor necrosis factor receptor system in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003, 48, 2533-2540.	6.7	137
12	DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 736-743.	0.5	135
13	TNF- α : a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. <i>Lupus</i> , 2003, 12, 454-461.	0.8	131
14	Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2009, 11, R186.	1.6	129
15	High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2019, 21, 107.	1.6	129
16	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 768-779.	0.5	128
17	Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2012, 14, R46.	1.6	127
18	Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16955-16960.	3.3	120

#	ARTICLE	IF	CITATIONS
19	A single nucleotide polymorphism in the <i>NCF1</i> gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1607-1613.	0.5	103
20	Role of early repeated renal biopsies in lupus nephritis. <i>Lupus Science and Medicine</i> , 2014, 1, e000018.	1.1	96
21	Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis. <i>PLoS ONE</i> , 2013, 8, e84450.	1.1	88
22	Excess atherosclerosis in systemic lupus erythematosus, a matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls. <i>PLoS ONE</i> , 2017, 12, e0174572.	1.1	88
23	Decreased Binding of Annexin V to Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 198-203.	1.1	87
24	Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1544-1549.	0.5	86
25	Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 372-379.	0.5	84
26	Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations. <i>Scientific Reports</i> , 2016, 6, 36025.	1.6	83
27	High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 363-369.	0.5	76
28	TNF- α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018, 5, e000260.	1.1	73
29	Platelet-derived S100A8/A9 and Cardiovascular Disease in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2016, 68, 1970-1980.	2.9	70
30	Prevention of cardiovascular disease in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2015, 14, 952-969.	2.5	69
31	A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 834-840.	0.5	68
32	Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1537-1543.	0.5	65
33	Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus. <i>Human Genetics</i> , 2019, 138, 141-150.	1.8	63
34	Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1363-1370.	0.5	60
35	Sex differences in clinical presentation of systemic lupus erythematosus. <i>Biology of Sex Differences</i> , 2019, 10, 60.	1.8	55
36	What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population-Based Study of Maternal and Fetal Outcomes in SLE and Pre-SLE. <i>Arthritis Care and Research</i> , 2016, 68, 988-994.	1.5	54

#	ARTICLE	IF	CITATIONS
37	Novel risk genes for systemic lupus erythematosus predicted by random forest classification. <i>Scientific Reports</i> , 2017, 7, 6236.	1.6	54
38	IFN- γ 1 with Th17 axis cytokines and IFN- γ 2 define different subsets in systemic lupus erythematosus (SLE). <i>Arthritis Research and Therapy</i> , 2017, 19, 139.	1.6	54
39	Kynurenine pathway is altered in patients with SLE and associated with severe fatigue. <i>Lupus Science and Medicine</i> , 2018, 5, e000254.	1.1	51
40	Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. <i>Autoimmunity</i> , 2014, 47, 67-76.	1.2	50
41	Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2016, 15, 203-209.	2.5	50
42	HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1018-1025.	0.5	49
43	Interferon (IFN)- γ is a potential mediator in lupus nephritis. <i>Lupus Science and Medicine</i> , 2016, 3, e000170.	1.1	48
44	Studies of microparticles in patients with the antiphospholipid syndrome (APS). <i>Lupus</i> , 2012, 21, 802-805.	0.8	46
45	Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. <i>Rheumatology</i> , 2013, 52, 501-509.	0.9	44
46	Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus. <i>Clinical and Experimental Immunology</i> , 2015, 181, 417-426.	1.1	43
47	Obstetric antiphospholipid syndrome. <i>Lupus Science and Medicine</i> , 2018, 5, e000197.	1.1	42
48	Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1063-1069.	0.5	41
49	Coronary Heart Disease in Systemic Lupus Erythematosus Is Associated With Interferon Regulatory Factor-8 Gene Variants. <i>Circulation: Cardiovascular Genetics</i> , 2013, 6, 255-263.	5.1	40
50	Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up. <i>Arthritis Research and Therapy</i> , 2015, 17, 109.	1.6	40
51	Ofatumumab treatment in lupus nephritis patients. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 552-555.	1.4	40
52	Case definitions in Swedish register data to identify systemic lupus erythematosus. <i>BMJ Open</i> , 2016, 6, e007769.	0.8	39
53	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	2.9	39
54	Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. <i>Lupus Science and Medicine</i> , 2015, 2, e000061-e000061.	1.1	38

#	ARTICLE	IF	CITATIONS
55	Microparticles in the blood of patients with SLE: Size, content of mitochondria and role in circulating immune complexes. <i>Journal of Autoimmunity</i> , 2019, 102, 142-149.	3.0	38
56	Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2008, 37, 352-359.	0.6	37
57	Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study. <i>Lupus</i> , 2017, 26, 1023-1033.	0.8	36
58	Early-onset Preeclampsia in Lupus Pregnancy. <i>Paediatric and Perinatal Epidemiology</i> , 2017, 31, 29-36.	0.8	36
59	Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 2869-2876.	6.7	35
60	Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 109-117.	0.5	35
61	Microparticles as autoantigens in systemic lupus erythematosus. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13010.	1.7	34
62	ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. <i>Rheumatology</i> , 2020, 59, 2237-2249.	0.9	34
63	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	1.1	31
64	NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 254-261.	0.5	30
65	Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease. <i>Lupus</i> , 2002, 11, 744-752.	0.8	28
66	Lifestyle habits and fatigue among people with systemic lupus erythematosus and matched population controls. <i>Lupus</i> , 2015, 24, 955-965.	0.8	28
67	Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1272-1279.	2.9	28
68	Sjögren Syndrome in Systemic Lupus Erythematosus: A Subset Characterized by a Systemic Inflammatory State. <i>Journal of Rheumatology</i> , 2020, 47, 865-875.	1.0	28
69	The A-1087IL-10 allele is associated with cardiovascular disease in SLE. <i>Atherosclerosis</i> , 2004, 177, 409-414.	0.4	27
70	Cardiovascular disease in systemic lupus erythematosus is associated with increased levels of biomarkers reflecting receptor-activated apoptosis. <i>Atherosclerosis</i> , 2018, 270, 1-7.	0.4	27
71	The antiphospholipid syndrome "often overlooked cause of vascular occlusions?". <i>Journal of Internal Medicine</i> , 2020, 287, 349-372.	2.7	27
72	Systemic Lupus Erythematosus Prevalence in Sweden in 2010: What Do National Registers Say?. <i>Arthritis Care and Research</i> , 2014, 66, 1710-1717.	1.5	26

#	ARTICLE	IF	CITATIONS
73	Antiphospholipid Antibodies in Lupus Nephritis. PLoS ONE, 2016, 11, e0158076.	1.1	26
74	Increased Serum Levels of the $\alpha\beta$ Neutralizing sST ₂ in Limited Cutaneous Systemic Sclerosis. Scandinavian Journal of Immunology, 2015, 82, 269-274.	1.3	25
75	Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA-DRB1 Genotype Associations and Immunological and Clinical Manifestations. ACR Open Rheumatology, 2022, 4, 27-39.	0.9	25
76	Genetic Risk Factors in Lupus Nephritis and IgA Nephropathy – No Support of an Overlap. PLoS ONE, 2010, 5, e10559.	1.1	24
77	Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL. Lupus, 2018, 27, 1470-1478.	0.8	24
78	Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives. Arthritis Research and Therapy, 2019, 21, 62.	1.6	24
79	Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 2011, 40, 363-372.	0.6	23
80	Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome. Thrombosis Research, 2014, 133, 936-944.	0.8	23
81	Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. Seminars in Arthritis and Rheumatism, 2016, 45, 684-690.	1.6	23
82	A Comprehensive Evaluation of the Relationship Between Different IgG and IgA Anti-Modified Protein Autoantibodies in Rheumatoid Arthritis. Frontiers in Immunology, 2021, 12, 627986.	2.2	23
83	Depressed serum IgM levels in SLE are restricted to defined subgroups. Clinical Immunology, 2017, 183, 304-315.	1.4	22
84	Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus. Rheumatology, 2020, 59, 3264-3274.	0.9	22
85	Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. Arthritis Research and Therapy, 2018, 20, 36.	1.6	20
86	Troponin I and echocardiography in patients with systemic sclerosis and matched population controls. Scandinavian Journal of Rheumatology, 2017, 46, 226-235.	0.6	19
87	Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis. Scandinavian Journal of Rheumatology, 2017, 46, 263-272.	0.6	18
88	Altered α 2-glycoprotein expression on microparticles in the presence of antiphospholipid antibodies. Journal of Thrombosis and Haemostasis, 2017, 15, 1799-1806.	1.9	17
89	Cytokine Profiles in Autoantibody Defined Subgroups of Systemic Lupus Erythematosus. Journal of Proteome Research, 2019, 18, 1208-1217.	1.8	17
90	Antiphospholipid Antibodies in Patients With Myocardial Infarction. Annals of Internal Medicine, 2019, 170, 277.	2.0	17

#	ARTICLE	IF	CITATIONS
91	Complement <i>C4</i> Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2022, 74, 1440-1450.	2.9	17
92	Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. <i>Clinical and Experimental Immunology</i> , 2018, 194, 27-38.	1.1	16
93	Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. <i>Diabetes Care</i> , 2019, 42, 1504-1511.	4.3	16
94	Epilepsy in systemic lupus erythematosus: prevalence and risk factors. <i>European Journal of Neurology</i> , 2020, 27, 297-307.	1.7	16
95	Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1387-1393.	1.6	16
96	The binding of SLE autoantibodies to mitochondria. <i>Clinical Immunology</i> , 2020, 212, 108349.	1.4	16
97	Sudanese and Swedish patients with systemic lupus erythematosus: immunological and clinical comparisons. <i>Rheumatology</i> , 2020, 59, 968-978.	0.9	15
98	Thrombin activatable fibrinolysis inhibitor (TAFI) – A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS). <i>Thrombosis Research</i> , 2017, 158, 168-173.	0.8	14
99	Muscle endurance, strength, and active range of motion in patients with different subphenotypes in systemic sclerosis: a cross-sectional cohort study. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 141-148.	0.6	14
100	Identification of MAMDC1 as a Candidate Susceptibility Gene for Systemic Lupus Erythematosus (SLE). <i>PLoS ONE</i> , 2009, 4, e8037.	1.1	14
101	DNA Methylation-Based Interferon Scores Associate With Sub-Phenotypes in Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 702037.	2.2	13
102	Multivariate strategy for the sample selection and integration of multi-batch data in metabolomics. <i>Metabolomics</i> , 2017, 13, 114.	1.4	12
103	A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts. <i>European Journal of Human Genetics</i> , 2019, 27, 432-441.	1.4	12
104	Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE. <i>Arthritis Research and Therapy</i> , 2021, 23, 132.	1.6	12
105	A Research Study of the Association between Maternal Microchimerism and Systemic Lupus Erythematosus in Adults: A Comparison between Patients and Healthy Controls Based on Single-Nucleotide Polymorphism Using Quantitative Real-Time PCR. <i>PLoS ONE</i> , 2013, 8, e74534.	1.1	11
106	Self-reported physical capacity and activity in patients with systemic sclerosis and matched controls. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 490-495.	0.6	11
107	Mortality and Functionality after Stroke in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2017, 44, 1590-1596.	1.0	11
108	Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1029.	2.2	11

#	ARTICLE	IF	CITATIONS
109	Infection hospitalisation in systemic lupus in Sweden. <i>Lupus Science and Medicine</i> , 2021, 8, e000510.	1.1	11
110	Mass spectrometry-based analysis of cerebrospinal fluid from arthritis patientsâ€™ immune-related candidate proteins affected by TNF blocking treatment. <i>Arthritis Research and Therapy</i> , 2019, 21, 60.	1.6	10
111	Interaction between the <i>STAT4</i> rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1183-1189.	0.5	10
112	A comparison of patientsâ€™ and physiciansâ€™ assessments of disease activity using the Swedish version of the Systemic Lupus Activity Questionnaire. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 474-483.	0.6	9
113	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1175-1182.	0.5	9
114	Variants in <i>BANK1</i> are associated with lupus nephritis of European ancestry. <i>Genes and Immunity</i> , 2021, 22, 194-202.	2.2	9
115	Gestational Diabetes Mellitus Risk in Pregnant Women With Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2022, 49, 465-469.	1.0	9
116	Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. <i>Lupus Science and Medicine</i> , 2021, 8, e000463.	1.1	8
117	Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?. <i>Autoimmunity Reviews</i> , 2019, 18, 102401.	2.5	7
118	Maternal Hypertensive Disorders in Pregnant Women With Systemic Lupus Erythematosus and Future Cardiovascular Outcomes. <i>Arthritis Care and Research</i> , 2021, 73, 574-579.	1.5	7
119	Toll-like receptors revisited; a possible role for TLR1 in lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 404-406.	0.5	7
120	Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a caseâ€“control study. <i>Lupus Science and Medicine</i> , 2021, 8, e000515.	1.1	7
121	Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2022, 9, e000607.	1.1	7
122	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	1.5	7
123	FRI0193â€¦2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
124	Could severe COVID-19 be considered a complementopathy?. <i>Lupus Science and Medicine</i> , 2020, 7, e000415.	1.1	6
125	Elevated IgA antiphospholipid antibodies in healthy pregnant women in Sudan but not Sweden, without corresponding increase in IgA anti-Î² ₂ glycoprotein I domain 1 antibodies. <i>Lupus</i> , 2020, 29, 463-473.	0.8	6
126	Contributions of de novo variants to systemic lupus erythematosus. <i>European Journal of Human Genetics</i> , 2021, 29, 184-193.	1.4	6

#	ARTICLE	IF	CITATIONS
127	Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE. <i>Lupus</i> , 2021, 30, 1289-1299.	0.8	6
128	High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients. <i>Lupus</i> , 2020, 29, 1412-1422.	0.8	4
129	Accumulation of antinuclear associated antibodies in circulating immune complexes is more prominent in SLE patients from Sudan than Sweden. <i>Scientific Reports</i> , 2020, 10, 21126.	1.6	4
130	Interferon activation status underlies higher antibody response to viral antigens in patients with systemic lupus erythematosus receiving no or light treatment. <i>Rheumatology</i> , 2021, 60, 1445-1455.	0.9	4
131	Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity. <i>Lupus Science and Medicine</i> , 2021, 8, e000471.	1.1	4
132	The Complex Relationship between C4b-Binding Protein, Warfarin, and Antiphospholipid Antibodies. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1299-1309.	1.8	3
133	Antiphospholipid antibodies in patients with myocardial infarction with and without obstructive coronary arteries. <i>Journal of Internal Medicine</i> , 2022, 291, 327-337.	2.7	3
134	AB0487â€¦Decreased SLE Disease Activity and Corticosteroid Usage and NO Renal Flares during Belimumab Treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 968.2-968.	0.5	2
135	S4D:5â€¦Targeted next-generation sequencing suggests novel risk loci in juvenile onset systemic lupus erythematosus. , 2018, , .		2
136	Antibodies to Porphyromonas gingivalis Are Increased in Patients with Severe Periodontitis, and Associate with Presence of Specific Autoantibodies and Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2022, 11, 1008.	1.0	2
137	Systems biology of SLE: biochemical characterisation of subgroups within sle for improved diagnosis and treatment. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A12.2-A12.	0.5	1
138	S4A:5â€¦High genetic risk score is associated with organ damage in systemic lupus erythematosus. , 2018, , .		1
139	Dr. Rossides, et al reply. <i>Journal of Rheumatology</i> , 2018, 45, 1070.2-1070.	1.0	1
140	P86â€¦The NCF1â€“339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. , 2020, , .		1
141	Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412092212.	0.9	1
142	POS1425â€¦ANTIBODIES TO PORPHYROMONAS GINGIVALIS ASSOCIATE WITH THE PRESENCE OF RHEUMATOID ARTHRITIS-RELATED AUTOANTIBODIES IN PATIENTS WITH PERIODONTITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 996.1-996.	0.5	1
143	OP0362â€¦Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. , 2018, , .		1
144	Title is missing!. <i>Arthritis Research</i> , 2005, 7, P105.	2.0	0

#	ARTICLE	IF	CITATIONS
145	Endothelial function and activation in women with systemic lupus erythematosus. Arthritis Research, 2005, 7, P148.	2.0	0
146	Title is missing!. Arthritis Research, 2005, 7, P143.	2.0	0
147	Title is missing!. Arthritis Research, 2005, 7, P122.	2.0	0
148	Low gene copy-number of complement C4A, the presence of HLA-DR3, and the presence of HLA-DR2 are independent and additive risk factors for human systemic lupus erythematosus. Molecular Immunology, 2010, 47, 2285-2285.	1.0	0
149	Ischemic vascular disease and antiphospholipid antibodies are associated with HLA-DRB1 *04/*13 alleles in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2012, 71, A57.3-A58.	0.5	0
150	AB0693â€¦Autoantibodies to the functionally active ring-domain of RO52/SSA associate with clinical activity in a subset of patients with lupus. Annals of the Rheumatic Diseases, 2013, 71, 678.7-678.	0.5	0
151	A10.23â€¦Stratification of SLE Patients for Improved Diagnosis and Treatment. Annals of the Rheumatic Diseases, 2013, 72, A80.2-A80.	0.5	0
152	FRI0271â€¦Stratification of sle patients for improved diagnosis and treatment. Annals of the Rheumatic Diseases, 2013, 72, A466.1-A466.	0.5	0
153	SAT0181â€¦Systems biology of SLE: Biochemical characterization of subgroups within SLE for improved diagnosis and treatment. Annals of the Rheumatic Diseases, 2013, 71, 532.3-532.	0.5	0
154	THU0162â€¦Thrombotic microangiopathy in renal biopsies from patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2013, 71, 210.2-210.	0.5	0
155	THU0309â€¦Coronary Heart Disease in Systemic Lupus Erythematosus is Associated with Interferon Regulatory Factor 8 Gene Variants. Annals of the Rheumatic Diseases, 2013, 72, A270.2-A270.	0.5	0
156	THU0530â€¦Blys and APRIL in Lupus Nephritis: Correlations with Serology - Blys as A Non-Invasive Predictor of Response. Annals of the Rheumatic Diseases, 2014, 73, 366.3-366.	0.5	0
157	FRI0172â€¦Utility of Swedish Register Data in Classifying Systemic Lupus. Annals of the Rheumatic Diseases, 2014, 73, 444.2-444.	0.5	0
158	THU0520â€¦Interferon (IFN)-Lambda1/3, but not IFN-Alpha, is A Marker of Poor Response to Treatment in Lupus Nephritis. Annals of the Rheumatic Diseases, 2014, 73, 363.1-363.	0.5	0
159	SAT0401â€¦Antiphospholipid Antibodies in Lupus Nephritis and Their Role in Long-Term Outcome. Annals of the Rheumatic Diseases, 2015, 74, 804.2-804.	0.5	0
160	OP0160â€¦Characterization of Systemic Lupus Erythematosus Subgroups with Features of Antiphospholipid or Sjögrens's Syndrome Utilizing Affinity Proteomics. Annals of the Rheumatic Diseases, 2016, 75, 116.2-116.	0.5	0
161	OP0171â€¦Prognosis of Stroke Patients with Systemic Lupus Erythematosus: A Population-Based Cohort Study: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 120.2-120.	0.5	0
162	A6.15â€¦Characterisation of systemic lupus erythematosus subgroups with features of antiphospholipid or sjögrens's syndrome utilising affinity proteomics. Annals of the Rheumatic Diseases, 2016, 75, A53.2-A53.	0.5	0

#	ARTICLE	IF	CITATIONS
163	05.01â€¦Protein profiling in plasma reveals molecular subgroups in systemic lupus erythematosus. , 2017, , .		0
164	AB0159â€¦Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus. , 2017, , .		0
165	SAT0239â€¦Late-onset neutropenia following rituximab treatment in systemic lupus erythematosus â€œ a role of the baff/april pathway. , 2017, , .		0
166	380â€¦Comparisons of fatigue, anxiety and depression in systemic lupus erythematosus, systemic sclerosis and anti-neutrophil cytoplasmatic antibody-associated vasculitis. , 2017, , .		0
167	237â€¦Ischaemic stroke in systemic lupus erythematosus, -distribution of subtypes and a risk genotype in the stat4 gene. , 2017, , .		0
168	Response to: â€œIncreased stroke incidence in systemic lupus erythematosus patients: risk factors or disease itself?â€™ by Bruzzese and Zullo. Annals of the Rheumatic Diseases, 2018, 77, e72-e72.	0.5	0
169	PS4:71â€¦Iga anti-phospholipid antibodies in swedish cases with systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. , 2018, , .		0
170	FRI0192â€¦A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
171	AB1401-HPRâ€¦SELF-REPORTED PHYSICAL FUNCTION AND ASSOCIATED FACTORS IN INDIVIDUALS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
172	P37â€¦Non-invasive biomarkers of disease activity in systemic lupus erythematosus. , 2020, , .		0
173	P89â€¦Epigenome-wide association study reveals differential DNA methylation in systemic lupus erythematosus patients with a history of ischemic heart disease. , 2020, , .		0
174	O30â€¦Complement deposition, C4d, on platelets is associated with vascular events and antiphospholipid antibodies in systemic lupus erythematosus. , 2020, , .		0
175	O32â€¦Skin proteome investigation in cutaneous lupus erythematosus (CLE) reveals novel unique disease pathways. , 2020, , .		0
176	Response to Comment on Norhammar et al. Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care 2019;42:1504â€œ1511. Diabetes Care, 2020, 43, e9-e9.	4.3	0
177	AB0318â€¦RISK FOR CONCOMITANT AUTOIMMUNITY IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME; A SWEDISH COHORT STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1184.1-1184.	0.5	0
178	POS0764â€¦EULAR RECOMMENDATION-BASED QUALITY INDICATORS (QIS) FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): ELABORATION, FINAL SET, PERFORMANCE AND INITIAL VALIDATION. Annals of the Rheumatic Diseases, 2021, 80, 635.2-636.	0.5	0
179	POS0184â€¦URINE-GALECTINE 3 BINDING PROTEIN (U-GAL3BP) IS A SENSITIVE MARKER OF KIDNEY INFLAMMATION AND RESPONSE TO TREATMENT IN LUPUS. Annals of the Rheumatic Diseases, 2021, 80, 305.2-306.	0.5	0
180	POS0009â€¦THE RELATIONSHIP BETWEEN DIFFERENT IGG AND IGA ANTI-MODIFIED PROTEIN AUTOANTIBODIES IN RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 206.1-207.	0.5	0

#	ARTICLE	IF	CITATIONS
181	Autoantibodies to the functionally active RING-domain of Ro52/SSA associate with clinical activity in a subset of patients with lupus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A40.1-A40.	0.5	0
182	OP0101-HPRâ€...QUALITY OF LIFE IN PEOPLE WITH SYSTEMIC SCLEROSIS WITH DIFFERENT DEGREES OF LUNG DISEASE - A CROSS-SECTIONAL STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 66.3-66.	0.5	0
183	AB0127â€...ACCUMULATION OF ANTI-NUCLEAR ASSOCIATED AUTOANTIBODIES IN CIRCULATING IMMUNE COMPLEXES IS MORE PROMINENT IN SLE PATIENTS FROM SUDAN COMPARED TO SWEDEN. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1364-1365.	0.5	0
184	THU0224â€...SKIN PROTEOME INVESTIGATION IN CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) REVEALS NOVEL UNIQUE DISEASE PATHWAYS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 339.2-339.	0.5	0
185	SAT0204â€...COMPARING OCCURRENCE AND CLINICAL SIGNIFICANCE OF ANTI-PHOSPHOLIPID AUTOANTIBODIES AMONG SUDANESE AND SWEDISH SLE PATIENTS USING CONVENTIONAL AND NATION-BASED CUTOFFS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1044.2-1045.	0.5	0
186	Factors Associated With Self-Reported Capacity to Walk, Jog and Run in Individuals With Systemic Lupus Erythematosus. <i>Archives of Rheumatology</i> , 2021, 36, 89-100.	0.3	0
187	Long term outcome after a first myocardial infarction. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
188	Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE. <i>Rheumatology</i> , 0, , .	0.9	0